Clinical Trial Update: LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

View source ↗

Summary

Australia granted marketing approval for afatinib under the Special Access Scheme (Named Patient Use) for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gilotrif (Afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Status: APPROVED_FOR_MARKETING